echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > To Biao Yangzijiang and Hengrui!

    To Biao Yangzijiang and Hengrui!

    • Last Update: 2021-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the official website of the State Food and Drug Administration showed that the Shijiazhuang four drugs' dexmedetomidine hydrochloride injection was approved for production in imitation 3 categories
    .


    According to data from Minai.


    September 09, 2021, release of drug approval documents pending receipt

    Data show that dexmedetomidine is an α2-adrenergic receptor agonist, which is mainly used for tracheal intubation and sedation during mechanical ventilation in patients undergoing general anesthesia
    .

    Sales of terminal dexmedetomidine injections in public medical institutions in China in recent years (unit: 100 million yuan)

    Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern

    Dexmedetomidine hydrochloride injection has been included in the national medical insurance and is a major clinical anesthetic
    .


    According to data from Meinenet, the sales of terminal dexmedetomidine injections in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly in recent years, and it will be close to 4 billion yuan in 2020.


    It is worth mentioning that Yangtze River Pharmaceutical Group’s dexmedetomidine hydrochloride injection won the exclusive bid in the centralized procurement of 4+7 and alliance areas, and its market share in China’s public medical institutions has rapidly increased, from less than 1 in 2018.


    Source: Meinenet MED2.


    In addition, dexmedetomidine hydrochloride injection has 7 companies including Jiangsu Zhengda Fenghai Pharmaceutical, Chenxin Pharmaceutical, Yunnan Longhai Natural Plant Pharmaceuticals, etc.


    Source: official website of the State Food and Drug Administration, Mi Nei.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.